INT103251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2002
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 9.36
Pain Relevance 8.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Calca) extracellular region (Calca) nucleus (Calca)
intracellular (Calca) cytoplasm (Calca)
Anatomy Link Frequency
neuronal 4
neurons 4
blood 2
cardiovascular system 2
skin 2
Calca (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 209 100.00 Very High Very High Very High
qutenza 191 100.00 Very High Very High Very High
substance P 35 100.00 Very High Very High Very High
calcitonin gene related peptide 28 100.00 Very High Very High Very High
bradykinin 25 100.00 Very High Very High Very High
Calcitonin gene-related peptide 25 100.00 Very High Very High Very High
Neurotransmitter 20 100.00 Very High Very High Very High
Glutamate 7 100.00 Very High Very High Very High
dorsal root ganglion 87 99.76 Very High Very High Very High
Sumatriptan 1 99.50 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pain 229 100.00 Very High Very High Very High
Nociception 94 100.00 Very High Very High Very High
Ganglion Cysts 91 99.76 Very High Very High Very High
Diabetes Mellitus 261 99.48 Very High Very High Very High
Increased Venous Pressure Under Development 24 98.72 Very High Very High Very High
Amputation 3 96.80 Very High Very High Very High
Muscular Spasm 4 96.64 Very High Very High Very High
Compartment Syndromes 1 95.60 Very High Very High Very High
Coronary Artery Disease 8 94.72 High High
Cv Unclassified Under Development 11 94.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Administration of ruthenium red (1 mg/kg(-1), i.p.), vanilloid receptor antagonist, and sumatriptan (50 mg/kg(-1), i.p.), a CGRP release inhibitor, attenuated diabetes and SHS induced decrease in nociceptive threshold and increase in serum nitrite oxide levels.
Negative_regulation (inhibitor) of Localization (release) of CGRP associated with nociception, sumatriptan, diabetes mellitus and antagonist
1) Confidence 0.43 Published 2008 Journal Yakugaku Zasshi Section Abstract Doc Link 18981706 Disease Relevance 1.45 Pain Relevance 0.84
The substantial increase of CGRP release evoked by noxious heat (47 degrees C) was diminished under muscarine by >50% in the WT and M4 KO animals but remained unaltered in the M2 KO mice.
Negative_regulation (diminished) of Localization (release) of CGRP associated with calcitonin gene-related peptide
2) Confidence 0.43 Published 2002 Journal J. Neurosci. Section Abstract Doc Link 12045234 Disease Relevance 0.37 Pain Relevance 0.55
Both L768242 and (+)-AM1241 dose dependently (EC50 of 3.6 and 4.5 nM, respectively) reduced capsaicin-induced calcitonin gene-related peptide (CGRP) release.
Negative_regulation (reduced) of Localization (release) of CGRP associated with qutenza and calcitonin gene-related peptide
3) Confidence 0.41 Published 2006 Journal Eur. J. Neurosci. Section Abstract Doc Link 16553616 Disease Relevance 0.25 Pain Relevance 0.95
Noxious heat-induced calcitonin gene-related peptide release showed clear deficits (<50%) in TRPV1 deficient skin, but the stimulated calcitonin gene-related peptide release from the isolated skull dura was unaffected.
Neg (unaffected) Negative_regulation (unaffected) of Localization (release) of calcitonin in skin associated with calcitonin gene-related peptide
4) Confidence 0.32 Published 2005 Journal Neuroscience Section Abstract Doc Link 16165301 Disease Relevance 0.07 Pain Relevance 0.55
The role of TRPV1 in the cardiovascular system has been addressed: 1) Infusion of TRPV1 agonists significantly alters blood pressure, which could be mostly reversed by selective TRPV1 antagonists [24,25]; 2) Ablation of TRPV1 expressing C fiber terminals by capsaicin or resiniferatoxin (RTX) results in the loss of CGRP release, increased plasma renin activity, and an inability to control salt loading by the kidneys [14]; 3) Activation of TRPV1 or ASIC3 by protons during ischemia mediates a sympathoexcitatory reflex that is abolished by RTX treatment [5,26].
Negative_regulation (loss) of Localization (release) of CGRP in cardiovascular system associated with c fibre, qutenza, ischemia, antagonist, agonist and calcitonin gene-related peptide
5) Confidence 0.20 Published 2006 Journal Mol Pain Section Body Doc Link PMC1563450 Disease Relevance 0.18 Pain Relevance 0.56
We propose that reduction of PG levels may contribute to deleterious vascular effects by decreasing sensitization of TRPV1 and subsequent reduction of CGRP and SP release.
Negative_regulation (reduction) of Localization (release) of CGRP associated with substance p and calcitonin gene-related peptide
6) Confidence 0.20 Published 2006 Journal Mol Pain Section Body Doc Link PMC1563450 Disease Relevance 0.38 Pain Relevance 0.62
Pretreatment with capsazepine, an inhibitor of vanilloid receptor-1 activation, and with KT5720, an inhibitor of protein kinase A, reversed GG-induced increases in CGRP release from DRG neurons.
Negative_regulation (reversed) of Localization (release) of CGRP in neurons associated with dorsal root ganglion
7) Confidence 0.19 Published 2010 Journal Biosci. Biotechnol. Biochem. Section Abstract Doc Link 20378988 Disease Relevance 0.37 Pain Relevance 0.22
TRPV1 mediated CGRP release could play a role in increasing blood supply to malignancies of the GI tract; the beneficial effect of COX inhibitors in this regard may arise from their ability to reduce TRPV1-mediated CGRP release and inhibition of PG-mediated angiogenesis.
Negative_regulation (reduce) of Localization (release) of CGRP in blood associated with calcitonin gene related peptide
8) Confidence 0.16 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647151 Disease Relevance 0.61 Pain Relevance 0.89
If untreated, this might lead to more serious complications, which include changes in microvascular function due to decreased release of CGRP, neuronal loss, development of gangrene and total loss of sensation leading to amputation.
Negative_regulation (decreased) of Localization (release) of CGRP in neuronal associated with amputation and increased venous pressure under development
9) Confidence 0.14 Published 2008 Journal Mol Pain Section Body Doc Link PMC2275252 Disease Relevance 1.22 Pain Relevance 0.31
This effect is TRPV1 specific as it was inhibited by capsazepine and suggested to occur as a result of CGRP and tachykinin release upon TRPV1 activation [86].
Negative_regulation (result) of Localization (release) of CGRP associated with calcitonin gene related peptide
10) Confidence 0.13 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2647151 Disease Relevance 0.64 Pain Relevance 0.58
If untreated, this might lead to more serious complications, which include changes in microvascular function due to decreased release of CGRP, neuronal loss, development of gangrene and total loss of sensation leading to amputation.
Negative_regulation (decreased) of Localization (release) of CGRP in neuronal associated with amputation and increased venous pressure under development
11) Confidence 0.10 Published 2008 Journal Mol Pain Section Body Doc Link PMC2275252 Disease Relevance 1.22 Pain Relevance 0.31
In central sensitization, wide-range function neurons of the spinal cord erroneously perceive non-nociceptive input (such as that from muscle spindles) as nociceptive.39 In cell cultures and animal studies, BoNTA diminishes the release of pain neurotransmitters such as substance P, calcitonin gene-related peptide, and bradykinin.40
Negative_regulation (diminishes) of Localization (release) of calcitonin in neurons associated with nociception, pain, central sensitization, bradykinin, calcitonin gene-related peptide, spinal cord, neurotransmitter and substance p
12) Confidence 0.03 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004649 Disease Relevance 1.45 Pain Relevance 1.12
In diminishing synaptic acetylcholine, the co-release of local factors for nociceptive transmission, such as calcitonin-gene-related protein (CGRP), glutamate, substance P and bradykinin (Arezzo 2002), is reduced as well.
Negative_regulation (reduced) of Localization (release) of calcitonin-gene-related protein associated with nociception, glutamate, bradykinin and substance p
13) Confidence 0.03 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656321 Disease Relevance 1.14 Pain Relevance 1.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox